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Abstract
Purpose Here, the expression of F4/80 on the cell surface of
murine macrophages was exploited to develop a novel imag-
ing tracer that could visualize macrophages in vivo.
Methods The immunoreactive fraction and IC50 of anti-F4/80-
A3-1, conjugated with diethylenetriaminepentaacetic acid
(DTPA) and radiolabelled with 111In, were determined in vitro
using murine bone marrow-derived macrophages. In vivo
biodistribution studies were performed with 111In-anti-F4/80-
A3-1 and isotype-matched control antibody 111In-rat IgG2b at
24 and 72 h post-injection (p.i.) in SCID/Beige mice bearing
orthotopic MDA-MB-231 xenografts. In some studies mice
were also treated with liposomal clodronate. Macrophage con-
tent in tissues was determined immunohistochemically. Micro-
single photon emission computed tomography (SPECT)/CT
images were also acquired.
Results In vitro binding assays showed that 111In-anti-F4/80-
A3-1 specifically binds F4/80 receptor-positive macrophages.
The immunoreactivity of anti-F4/80-A3-1 was 75 % and IC50
was 0.58 nM. In vivo, injection of 10 or 100 μg 111In-anti-F4/
80-A3-1 resulted in splenic uptake of 78 %ID/g and 31 %ID/
g, respectively, and tumour uptake of 1.38 %ID/g and
4.08 %ID/g, respectively (72 h p.i.). Liposomal clodronate
treatment reduced splenic uptake of 10 μg 111In-anti-F4/80-
A3-1 from 248 %ID/g to 114 %ID/g and reduced 111In-anti-
F4/80-A3-1 uptake in the liver and femur (24 h p.i.). Tracer
retention in the blood and tumour uptake increased (24 h p.i.).
Tumour uptake of 111In-anti-F4/80-A3-1 was visualized by
microSPECT/CT. Macrophage density in the spleen and liver
decreased in mice treated with liposomal clodronate. Uptake
of 111In-rat IgG2b was lower in the spleen, liver and femur
when compared to 111In-anti-F4/80-A3-1.
Conclusion Radiolabelled anti-F4/80-A3-1 antibodies specif-
ically localize in tissues infiltrated by macrophages in mice
and can be used to visualize tumours. The liver and spleen act
as antigen sink organs for macrophage-specific tracers.
Keywords Macrophages . Tumour-associatedmacrophages .
F4/80 . Imaging . 111In
Introduction
Macrophages play an important role in the phagocytosis of
microbes and in the regulation of developmental processes
and pathophysiological responses, including inflammation
and tumour growth [1]. Monocytes, once resident in tissues,
acquire tissue-specific characteristics and express cell surface
proteins in response to signals within the microenvironment,
which determine their local function. During acute inflamma-
tion, M1 macrophages become activated through a classical
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111In-anti-F4/80-A3-1 antibody: a novel tracer
to image macrophages
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pathway and are able to kill and phagocytose tumour cells.M2
macrophages, activated alternatively, are involved in key pro-
cesses of tumour progression, including angiogenesis, metas-
tasis and immunosuppression [2].
The F4/80 receptor is generally considered a murine pan-
macrophagemarker [3] and is expressed on tumour-associated
macrophages (TAMs). The production of anti-F4/80-A3-1 an-
tibodies was first reported in 1981 [3]. The expression of the
F4/80 receptor on macrophages plays a role in peripheral tol-
erance [4] and T cell-mediated immune response [5].
Expression can occur on mature bone marrow stromal macro-
phages, Kupffer cells [6], eosinophils after parasitic infection
[7] and in alveoli, albeit at low levels [8]. Although M1 and
M2 macrophage phenotypes are not stable as they can change
in response to environmental signals [9], TAMs mostly polar-
ize towards the M2 phenotype [10]. Consequently, the density
of TAMs is associated with poor prognosis [11–15]. Therapies
targeting the interaction between TAMs and tumour cells have
therefore gained much interest and tend to focus either on
polarizing TAMs towards a tumouricidal phenotype using ag-
onists, inhibitors and other agents or on decreasing the number
of TAMs in tumour tissue [16–20].
The multiple therapies targeting TAMs could offer new
routes in cancer therapy. Being able to image TAMs could
aid in the development of novel macrophage-targeted drugs
and could be applied to monitor the kinetics of macrophage
infiltration in response to antibody-based immunotherapies
engaging innate immune cells, such as therapy with anti-
epidermal growth factor receptor (EGFR) antibodies [16]. In
addition, TAM-specific radiotracers might ultimately allow
the monitoring of prognosis of patients or aid the selection
of patients that are more likely to respond to these therapies.
Macrophages and other phagocytic cells have previously
been imaged through passive uptake of radiolabelled
PEGylated, mannosylated liposomes, and dextran nanoparti-
cles [21–23], the dual magneto-optical imaging probe PG-Gd-
NIR813 [24], and iron oxide or functionally derivatized nano-
particles [25, 26]. More targeted methods of non-invasively
imaging TAMs include 99mTc-labelled anti-mannose receptor
nanobodies [27] and radiolabelled folic acid [28].
In this article, we describe the radiolabelling and
in vitro and in vivo characterization of a novel anti-F4/80-
A3-1 antibody-based radiotracer for specific imaging of
macrophages.
Materials and methods
Synthesis of ITC-DTPA-conjugated antibodies
Rat anti-mouse anti-F4/80-A3-1 antibody (AbD Serotec,
Kidlington, UK; monoclonal; clone Cl:A3-1) and rat IgG2b
isotype control (R&D Systems, Abingdon, UK) were dialysed
against 1:1 phosphate-buffered saline (PBS):water to re-
move sodium azide. Antibodies were conjugated under
strict metal-free conditions with isothiocyanatobenzyl-
diethylenetriaminepentaacetic acid (ITC-DTPA, Macrocyclics,
Dallas, TX, USA) in 0.1 M NaHCO3, pH 9.5, using a
10-fold molar excess of ITC-DTPA for 1 h at room tempera-
ture (RT). Unbound ITC-DTPA was removed by dialysis
against 0.1 M 2-(N-morpholino)ethanesulfonic acid (MES),
pH 5.5.
Radiolabelling
111InCl3 (Mallinckrodt, Petten, The Netherlands) was added to
ITC-DTPA-anti-F4/80-A3-1 or -rat IgG2b for 1 h at RT in
0.1MMES buffer pH 5.4. For biodistribution studies, approx-
imately 80 MBq was added to 4 μg ITC-DTPA-anti-F4/80-
A3-1 or -rat IgG2b. For single photon emission computed
tomography (SPECT) studies, 43 MBq was added to 20 μg
ITC-DTPA-anti-F4/80-A3-1 or -rat IgG2b. Free 111In was
complexed by adding ethylenediaminetetraacetic acid
(EDTA; final concentration of 5 mM). Labelling efficiency
and radiochemical purity were determined using instant thin-
layer chromatography and fast protein liquid chromatography
(see Supplementary figures for details). To obtain a radio-
chemical purity ≥95%, 111In-labelled antibodies were purified
by gel filtration on a PD10 column (GE Healthcare Life
Sciences) eluted with PBS containing 0.5 % bovine serum
albumin (BSA).
Isolation and ex vivo differentiation of macrophages
Intact femurs were removed from SCID/Beige mice, eutha-
nized by CO2/O2, and placed into PBS on ice. Under sterile
conditions, femurs were submerged in 70 % ethanol, PBS and
Dulbecco’s modified Eagle’s medium (DMEM) and Ham’s
F12 (DMEM-F12). Femurs were flushed with DMEM-F12
and harvested bone marrow cells (10×106 cells per femur)
were pelleted at 300 g for 5 min at 4 °C, filtered through a
100-μm nylon mesh (BD Biosciences) and plated at 10×106
cells per 100×20mm dish in DMEM-F12 with 10% fetal calf
serum (FCS; Invitrogen; Life Technologies), 1 % glutamine,
1 % penicillin/streptomycin (Invitrogen) and 100 μg/ml re-
combinant mouse M-CSF (R&D Systems) (full DMEM-
F12) at 37 °C in a humidified 5 % CO2 atmosphere for 7 days
in total, before being harvested by heat shock from 37 to 4 °C.
Animal experiments were approved by the local Animal
Welfare Committee in accordance with Dutch legislation and
carried out in accordance with their guidelines.
Cell culture
MDA-MB-231 human breast cancer cells, negative for F4/80,
were cultured in RPMI-1640 supplemented with 10 % (v/v)
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FCS and 1% glutamine (Invitrogen). Cells were maintained at
37 °C in a humidified 5 % CO2 atmosphere and routinely
passaged using a 0.25 % trypsin/EDTA solution (Invitrogen).
Flow cytometry
Macrophages (0.5×106) were stained with anti-mouse CD11b-
FITC and anti-mouse F4/80-PE antibodies (Biolegend) at 4 °C
for 30 min in PBS with 0.5 % BSA. Cells (10,000) were
analysed with a FACSCalibur (BD Biosciences) using
forward/side scatter characteristics and analysed using
CellQuest software (BD Biosciences). Samples stained
with each fluorophore separately were used to alter
voltage and amplitude gain settings to allow for
compensation.
In vitro binding assays
Immunoreactive fractions of 111In-anti-F4/80-A3-1 and 111In-
rat IgG2b were determined as described by Lindmo et al. [29].
A serial dilution of cells (1 ml) was prepared in DMEM-F12
supplemented with 0.5 % BSA; 2 kBq of radiolabelled tracer
(1 ng) was added. Non-specific binding was determined by
incubation in the presence of a blocking dose of unlabelled
antibody (10 μg). After 30 min at 37 °C, cells were centri-
fuged, washed and the supernatant collected. Pellets were
lysed in 0.1 M NaOH. The activity in the supernatant
(unbound) and pellets (bound) was measured in a gamma
counter.
The concentration required to inhibit binding of 111In-anti-
F4/80-A3-1 by 50 % (IC50) was determined using 5×10
6
macrophages in DMEM-F12 supplemented with 0.5 % BSA
incubated with increasing concentrations of ITC-DTPA-anti-
F4/80-A3-1 (50 pM to 70 nM) and 2 kBq of radiolabelled
tracer (1 ng). After 30 min incubation on ice and washing,
cell-bound activity was measured in a gamma counter. Data
were analysed using GraphPad Prism (version 5.03).
Production of liposomes
Clodronate liposomes were prepared by injecting 1 ml of a
lipid solution of 1 mmol/ml in ethanol [containing dipalmitoyl
p h o s p h a t i d y l c h o l i n e ( D P P C ) , d i p a l m i t o y l
phosphatidylglycerol (DPPG) (both from Lipoid GmbH,
Ludwigshafen, Germany) and cholesterol (Sigma-Aldrich) in
a molar percentage of 62, 5 and 33 % of total lipid, respec-
tively] in 9 ml of an aqueous solution of 100mg/ml clodronate
disodium salt (Sigma-Aldrich). Subsequently, the 10 ml crude
liposome dispersion was sized by multiple extrusion at 60 °C
using a medium pressure extruder (Avestin, Mannheim,
Germany) equipped with two stacked polycarbonate mem-
brane filters, one with a pore size of 200 nm on top of one
with 100 nm pores. Alcohol and free clodronate (not
incorporated in liposomes) were removed by repeated cycles
of ultrafiltration and replacement of the filtrate with PBS. The
resulting formulation consisted of liposomes of approximately
125 nm in diameter as measured by dynamic light scattering,
with a polydispersity index of 0.05 and a zeta potential of
approximately −30 mV. Content determination was done by
extraction using the organic phase for lipid determination
(HPLC followed by evaporative light scattering detection)
and the aqueous phase to assess the clodronate content (UV
spectrophotometry at 238 nm after formation of clodronate
complex with CuSO4 solution). The liposomes contained ap-
proximately 2 mg clodronate/ml and 70 μmol total lipid/ml.
Empty liposomes were prepared in the same manner using
PBS instead of the aqueous clodronate solution.
Biodistribution studies
In biodistribution studies, female SCID/Beige mice were in-
oculated in the mammary fad pad with 50 μl RPMI-1640
medium containing 2×106MDA-MB-231 cells supplemented
with BD Matrigel Basement Membrane Matrix (BD
Biosciences, Franklin Lakes, NJ, USA). When tumours
reached 150–400 mm3 in volume, mice were injected intrave-
nously (i.v.) with purified 10μg (1MBq) or 100 μg 111In-anti-
F4/80-A3-1 (1.6MBq) or 111In-rat IgG2b (1.5MBq) in 200 μl
PBS, 0.5 % BSA. Mice were euthanized by CO2/O2 asphyx-
iation at 24 or 72 h post-injection (p.i.). For biodistribution
studies involving liposomes, 300 μl of the liposome mix was
injected i.v. per mouse, twice in 4 days (5 days and 24 h, i.e.
just prior to injection of the tracer, before euthanasia). Blood,
tumour and the major organs and tissues were dissected,
weighed and counted in a gamma counter. Blood samples
were also taken at 1 h p.i. of 10 μg 111In-F4/80 or 111In-rat
IgG2b in mice treated with or without clodronate or empty
liposomes. Tumours, spleens and livers were flash frozen for
further immunohistochemical analysis. The percentage
injected dose per gram (%ID/g) of each sample was
calculated.
Immunohistochemistry
Tissues were snap-frozen and sections were fixed in acetone,
blocked for 30min with 5% normal goat serum and incubated
with rat anti-mouse anti-CD68 antibody (AbD Serotec)
followed by a secondary biotinylated goat anti-rat antibody.
Sections were then exposed to an avidin-biotin-enzyme com-
plex (Vector Laboratories, Burlingame, CA, USA) and were
incubated with diaminobenzidine for development followed
by a haematoxylin counterstain. The number of CD68-
positive cells per 1.5 mm×1.5 mm square (as highlighted in
×10 image) was calculated for the spleen, liver and tumour
sections averaged from six to eight squares/areas of tissue
from one sample.
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MicroSPECT imaging
In microSPECT imaging studies, mice with orthotopic MDA-
MB-231 tumour xenografts were injected i.v. with 100 μg
purified 111In-F4/80 (14 MBq). Mice were euthanized at
24 h p.i. and scanned using the U-SPECT-II/CT (4 frames of
15 min; spatial resolution 160 μm, 65 kV, 615 μA) (MILabs)
[30]. A CT scan was also taken for anatomic reference. Mice
were euthanized prior to imaging, rather than imaged under
anaesthesia, to allow a proper comparison of the SPECT/CT
imaging data with the biodistribution data. SPECT scans, four
frames combined, were reconstructed using an ordered subset
expectation maximization algorithm, with a voxel size of
0.4 mm (MILabs).
Statistical analysis
In in vitro and biodistribution studies, all values are given as
mean ± standard deviat ion. Stat is t ical analysis in
biodistribution studies and tabular data (Fig. 3 and
Table 1) was performed using a two-way analysis of
variance (ANOVA) with Tukey’s multiple comparisons
test with GraphPad Prism Software (version 5.03). Other data
were analysed by a one-sample t test. Statistical signif-
icance was set at *p≤0.05, **p≤0.01, ***p≤0.001 and
****p≤0.0001.
Results
Synthesis and radiolabelling of antibodies
111In-anti-F4/80-A3-1 and 111In-rat IgG2b were prepared
with a maximum specific activity of 12 and 2 MBq/
μg, respectively. After purification, a radiochemical pu-
rity of ≥95 % was achieved for both tracers (data not
shown). A sodium dodecyl sulphate polyacrylamide gel
electrophoresis (SDS-PAGE) gel was run in the evaluation of
the antibody integrity, after conjugation, and it showed a band
at both 140 and 50 kDa, suggesting the presence of a F(ab)
fragment in the preparation.
Flow cytometry
Bone marrow cells isolated from murine femoral bone mar-
row were differentiated to CD11b+/F4/80+ macrophages.
MDA-MB-231 human breast cancer cells were CD11b−/F4/
80− (data not shown).
In vitro binding assays
The immunoreactive fraction of 111In-anti-F4/80-A3-1
fo r F4 /80 recep to r s was 75 % (F ig . 1a and
Supplementary Figure 1). 111In-anti-F4/80-A3-1 did not
bind MDA-MB-231 cells (Fig. 1c, d), nor did 111In-rat
IgG2b bind F4/80-positive macrophages (Fig. 1a, b;
p<0.01). The addition of a blocking dose of ITC-
DTPA-anti-F4/80-A3-1 decreased binding of 111In-anti-
F4/80-A3-1 to macrophages from 10.9±2.8 to 0.6±
0.1 % (Fig. 1b), indicating specific binding of 111In-
anti-F4/80-A3-1 to macrophages. The IC50 was 0.58 nM
(Fig. 2).
Biodistribution studies
The results of the biodistribution studies of 10 and
100 μg 111In-anti-F4/80-A3-1 at 24 and 72 h p.i. are
summarized in Table 1. 111In-anti-F4/80-A3-1 (10 μg)
in the circulation decreased from 1.27 %ID/g at 24 h
p.i. to 0.39%ID/g at 72 h p.i. Uptake of 111In-anti-F4/80-A3-1
in the tumour, liver and spleen (p≤0.001) also decreased;
however, tracer uptake in all three tissues increased relative
to blood. At 72 h p.i., the tumour to blood uptake ratio of
111In-anti-F4/80-A3-1 (10 μg) was 4.6 compared to 1.8 at
24 h p.i. The spleen to blood and liver to blood ratios also
increased from 195 to 201 and from 22 to 29, at 24 and 72 h
p.i., respectively.
Injection of 100 μg 111In-anti-F4/80-A3-1 resulted in
a lower splenic uptake than injection of 10 μg 111In-
anti-F4/80-A3-1: 30.94 %ID/g versus 78.23 %ID/g at
72 h p.i. (Table 1; p≤0.0001). Uptake of 111In-anti-F4/
80-A3-1 in the MDA-MB-231 tumour was higher at the
higher dose: 4.08 %ID/g versus 1.38 %ID/g.
Splenic uptake of 111In-anti-F4/80-A3-1 at 24 h p.i. was
markedly reduced after mice were treated with clodronate li-
posomes: 114.35 %ID/g compared to 247.88 %ID/g (p≤
0.0001), whereas uptake was unaffected in mice treated with
Table 1 Uptake (%ID/g) of 10 and 100 μg 111In-anti-F4/80-A3-1 at 24
and 72 h p.i. in tissues and organs of SCID/Beige mice with orthotopic
MDA-MB-231 tumours
10 μg at 24 h 10 μg at 72 h 100 μg at 72 h
Blood 1.27±0.61 0.39±0.31 0.42±0.16
Muscle 0.20±0.06 0.10±0.01 0.25±0.06
Tumour 2.01±0.20 1.38±0.34 4.08±0.27
Spleen 247.88±61.94 78.23±8.22 30.9±5.51
Pancreas 0.78±0.28 0.66±0.32 1.17±0.16
Kidney 17.35±1.80 8.15±0.95 11.10±0.97
Stomach 0.73±0.12 0.71±0.28 1.23±0.09
Duodenum 8.93±3.88 4.06±1.01 4.92±0.49
Liver 28.43±2.96 11.18±2.88 9.04±0.36
Tumour:blood 1.8±0.6 4.6±2.3 11.2±4.8
Data are presented as average±standard deviation (10 μg 24 h spleen,
100 μg 72 h n=4; rest n=5)
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empty liposomes (p>0.05; Fig. 3b). Splenic uptake of the
isotype-matched control antibody 111In-rat IgG2b was mark-
edly lower (12.70 %ID/g) than that of 111In-anti-F4/80-A3-1
(p≤0.0001).
Clodronate liposomal treatment resulted in decreased
uptake of 111In-anti-F4/80-A3-1 in both the liver (p≤
0.0001) and femur (p≤0.01) (10.51 and 3.73 %ID/g,
respectively) compared to the control group (28.43 and
7.81 %ID/g, respectively; Fig. 3a) at 24 h p.i. Most
importantly, uptake of 111In-anti-F4/80-A3-1 in the tu-
mour increased after clodronate treatment (5.67 %ID/g
compared to 2.01 %ID/g; p≤0.05). Figure 3c shows that
tumour to blood ratios of 111In-anti-F4/80-A3-1 did not
significantly differ in animals treated with or without
clodronate liposomes (p>0.05). Tumour uptake of
111In-rat IgG2b was significantly higher than 111In-anti-
F4/80-A3-1 (Fig. 3a; p≤0.0001), yet higher circulation
levels of 111In-rat IgG2b meant significantly lower tu-
mour to blood values for 111In-rat IgG2b than for 111In-
anti-F4/80-A3-1. Blood levels of 111In-anti-F4/80-A3-1
(10 μg) at 1 h p.i. were clearly higher after clodronate
treatment (50.43 %ID/g versus 6.18 %ID/g in control;
Table 2).
Immunohistochemistry
Figure 4 shows that macrophage content within the liver (p≤
0.001), spleen (p≤0.01) and tumour (p≤0.05) was lowered
significantly after treatment with clodronate liposomes, which
equalled 363±64, 1,552±274 and 586±260 per square,
respectively, when compared to controls (741±216, 2,
762± 566 and 842±389 per square, respectively).
Treatment of mice with empty liposomes did not affect
the macrophage content in tissues compared to controls
(data not shown).
MicroSPECT imaging
Fused SPECT/CT scans (Fig. 5) show that orthotopic MDA-
MB-231 tumour xenografts as well as macrophages in the
spleen and liver can be visualized. In addition, activity in the
kidney was visualized.
Fig. 1 In vitro binding
of 111In-anti-F4/80-A3-1 (a–d)
or isotype control 111In-rat IgG2b
(a, b) to macrophages (a, b) or
MDA-MB-231 cells (c, d). Cells
were also incubated in the
presence of a blocking dose of
antibody (b, d) to ascertain target-
mediated binding of each tracer.
Data are presented as mean±
standard deviation (111In-anti-F4/
80-A3-1: n=3/study; 111In-rat
IgG2b: n=2/study; experiments
were carried out twice)
Fig. 2 Competitive binding curve to determine the IC50 of ITC-DTPA-
anti-F4/80-A3-1 for macrophages. 111In-anti-F4/80-A3-1 was used as a
radioactive tracer. Data are presented as mean±standard deviation (n=2/
study; experiments were carried out twice)
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Discussion
In this study, we demonstrated that 111In-anti-F4/80-A3-1 al-
lows visualization of TAMs as well as macrophages in the
spleen and liver. MicroSPECT imaging also shows uptake of
the tracer in the kidneys.
In vitro studies showed that 111In-anti-F4/80-A3-1 specifi-
cally bound F4/80 receptor-positive macrophages with high
affinity. Supplementary Figures 2 and 3 show serum stability
up to 24 h after incubation in serum or PBS in vitro.
Preliminary ex vivo immunofluorescent staining showed that
21 % of all F4/80-positive cells are targeted by 111In-anti-F4/
80-A3-1 and that 111In-anti-F4/80-A3-1 mostly localized at
F4/80-positive cells (77 %; Supplementary Figure 4).
Initial in vivo experiments showed that 111In-anti-F4/80-A3-
1 at a protein dose of 10 μg per mouse cleared quickly from the
blood after injection of the tracer. This was thought to be due to
the presence of antigen sinks, mainly in the spleen and liver,
where uptake of the tracer was high at 248 and 28%ID/g at 24 h
p.i., respectively. The presence of antigen sinks was confirmed
by the observation that liver and spleen uptake were lower
when a higher dose of antibody was administered (100 μg per
mouse). Partial saturation of these sinks, by the injection of a
higher antibody dose, led to improved tumour uptake.
Subsequently, clodronate liposomes were used to decrease
the macrophage content within the spleen and liver. These
liposomes are selectively ingested by phagocytes and the
clodronate, able to kill macrophages, is released within these
cells once lysis of the liposomes has occurred [31].
Intravenous application of this liposome-mediated macro-
phage Bsuicide^ approach decreased the macrophage popula-
tion within the spleen and liver [31] as well as F4/80-positive
macrophages in the tumour microenvironment [32].
Administration of clodronate liposomes decreased uptake of
111In-anti-F4/80-A3-1 in the spleen and liver (Fig. 3), which
correlated with diminished macrophage density in these or-
gans. Furthermore, treatment of mice with clodronate lipo-
somes decreased the uptake of 111In-anti-F4/80-A3-1 in the
bone marrow and enhanced blood levels and uptake in the
tumour. Despite the tumour to blood ratio for 111In-anti-F4/
80-A3-1 being similar between control and liposome-treated
groups, the specificity of 111In-anti-F4/80-A3-1 for macro-
phages was demonstrated by the higher tumour to blood ratio
for 111In-anti-F4/80-A3-1 than for 111In-rat IgG2b. Treatment
with empty liposomes did not affect uptake of 111In-anti-F4/
80-A3-1 in most tissues and organs (Fig. 3), again indicating
that the effects seen after treatment with clodronate liposomes
is macrophage-specific, a tentative conclusion also supported
by the fact that at injection of 10 μg 111In-anti-F4/80-A3-1,
77 % of the tracer localized with the F4/80 receptor
(Supplementary Figure 4).
Fig. 3 Biodistribution of 10 μg
111In-anti-F4/80-A3-1 or isotype
control 111In-rat IgG2b at 24 h
p.i. in tissues and organs (a–b)
of mice treated with clodronate
liposomes or empty liposomes
(111In-anti-F4/80-A3-1). Isotype
control =111In-rat IgG2b. Tumour
to blood ratios of 10μg 111In-anti-
F4/80-A3-1 or 111In-rat IgG2b
at 24 h p.i. in mice treated with
clodronate liposomes or empty
liposomes (111In-anti-F4/
80-A3-1) or injected with isotype
control (111In-rat IgG2b) were
also calculated (c). All studies
were performed using SCID/
Beige mice with orthotopic
MDA-MB-231 tumour
xenografts. Data are mean±
standard deviation
(spleen: n=4; rest: n=5)
Table 2 Retention of 10 μg 111In-anti-F4/80-A3-1 or control
isotype 111In-rat IgG2b at 1 h p.i. in blood in tumour-bearing mice treated
with vehicle, clodronate liposomes or empty liposomes
Control Clodronate liposomes Empty liposomes Isotype control
6.18±0.76 50.43±11.07 21.77±3.59 32.37±0.97
Data are presented as mean±standard deviation (n=2)
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The main exception to this is the liver where treatment with
empty liposomes diminished uptake of 111In-anti-F4/80-A3-1
compared to the control group. This is thought to be due to the
partial saturation in the liver of joint mechanisms involved in
opsonization of liposomes as well as of Fc-mediated opsonization
of antibodies, here 111In-anti-F4/80-A3-1, prior to injection of the
tracer [33, 34]. Nevertheless, treatment with clodronate liposomes
significantly further diminished 111In-anti-F4/80-A3-1 uptake in
the liver compared to the group treated with empty liposomes
(p=0.01), suggesting that saturated opsonization only partially
reduced the tracer uptake and that decreased macrophage density
further reduced the hepatic uptake of the tracer.
Macrophage infiltration of the tumour was also affected by
clodronate treatment, yet the increase in 111In-anti-F4/80-A3-
1 uptake in the tumour after clodronate liposomes treatment is
a result of enhanced levels of the tracer in the blood.
Apart from fluorescently labelled anti-F4/80-A3-1 antibod-
ies being used to image arthritis in vivo [35], an intact antibody-
based approach to visualize tumour-associated macrophages
has not previously been attempted. Several targeted approaches
have instead included 99mTc-labelled anti-macrophage man-
nose receptor nanobodies [27] and radiofluorinated folic acid
to target the folate receptor on macrophages [28]. Both tracers
have a high tumour to blood ratio of approximately 23 and are
excellent tracers to follow TAMs for up to 90–180 min p.i. of
the tracer. However, with 111In-anti-F4/80-A3-1 macro-
phages could be monitored for up to 72 h p.i. This
could be a great advantage when using imaging tracers
to monitor response to existing or novel therapies that
interfere with macrophage-tumour cell interactions.
Fig. 4 Immunohistochemical
staining for macrophages with
anti-CD68 antibodies on frozen
5-μm sections of the spleen (a–c)
of mice treated with vehicle (a, c)
or clodronate liposomes (b).
Quantitative analysis of number
of CD68-positive cells per
square (=1.5 mm, see c) in the
liver, spleen and orthotopic
MDA-MB-231 tumour of mice
treated with vehicle or clodronate
liposomes (d). Data are
mean±standard deviation
(d: n=6 (spleen), n=8
(tumour/liver)). Magnification
equals ×40 (a, b) and ×10 (c)
Fig. 5 3-D volume projections of SPECT/CT scans taken 24 h p.i. of
100 μg 111In-anti-F4/80-A3-1 in mice with orthotopic MDA-MB-231
tumour xenografts. Visible are tumour (tu), liver (li), spleen (sp) and
kidneys (ki)
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Depending on the need of the tracer, the specific kinetics
and biodistribution of 111In-anti-F4/80-A3-1, or anti-F4/80-
A3-1 labelled with a shorter half-life radionuclide to compen-
sate for the shorter than usual circulating time of the antibody,
could provide a good alternative to the current armamentarium
of macrophage tracers. With an increased interest in develop-
ing drug strategies targeting tumour macrophages, a need for
imaging these macrophages preclinically has also arisen,
which might be met by the tracer presented here, if
future studies also prove promising. 111In-anti-F4/80-
A3-1, as a tracer targeting murine macrophages, therefore
has potential to become an important in vivo tool in
the development and characterization of novel macrophage-
targeted therapies.
In conclusion, 111In-anti-F4/80-A3-1 specifically visual-
ized the tumour and macrophages resident in tissues. The
spleen and liver act as antigen sink organs, which has im-
plications for the dose of 111In-anti-F4/80-A3-1 that should
be administered in order to see high tumour targeting.
These results imply that if 111In-anti-F4/80-A3-1 can be
used to monitor TAMs in vivo, its rapid uptake in non-
tumour tissues should first be prevented and circulation
time enhanced to achieve optimal tumour localization of
111In-anti-F4/80-A3-1. Alternatively, imaging TAMs could
also be further accomplished by developing a tracer specific
to M2 macrophages. This should lead to a comparatively
enhanced tumour uptake and diminished non-tumour tissue
uptake by circumventing M1 macrophages that were pres-
ent in the current antigen sinks leading to reduced tumour
uptake of 111In-anti-F4/80-A3-1.
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